Iterum Therapeutics Plc Stock

$1.03

4.20% today

Nasdaq, Jun 25, 08:17 pm CET

ISIN

IE00BF3W0Q35

Symbol

ITRM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Iterum Therapeutics Plc Stock price

$0.98

-21.82 95.69% 5Y

Nasdaq, Closing price Tue, Jun 24 2025

+0.04 4.14%

ISIN

IE00BF3W0Q35

Symbol

ITRM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$39.4m

Enterprise Value

$58.7m

Net debt

$19.4m

Cash

$12.7m

Shares outstanding

35.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 8.43

EV/Sales

- | 12.58

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-9.15%

Return on Equity

612.59%

ROCE

-55.36%

ROIC

-83.32%

Debt/Equity

-12.56

Financials (TTM | estimate)

Revenue

$0.0 | $4.7m

EBITDA

$-15.6m | $-14.5m

EBIT

$-16.2m

Net Income

$-22.6m | $-7.5m

Free Cash Flow

$-16.8m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

64.32% | 22.54%

EBIT

63.98%

Net Income

36.57% | 70.04%

Free Cash Flow

60.62%

Margin (TTM | estimate)

Gross

EBITDA

- | -310.73%

EBIT

Net

- | -160.61%

Free Cash Flow

EPS

$-0.66

FCF per Share

$-0.47

Short interest

2.74%

Employees

14.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,904 stocks worldwide.

Get Started for Free Today

Iterum Therapeutics Plc Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Iterum Therapeutics Plc forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Iterum Therapeutics Plc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Iterum Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.60 0.60	- -
Gross Profit	-0.60 -0.60	- -
- Selling and Administrative Expenses	8.57 8.57	13% 13% -
- Research and Development Expense	7.07 7.07	81% 81% -
EBITDA	-16 -16	64% 64% -
- Depreciation and Amortization	0.62 0.62	53% 53% -
EBIT (Operating Income) EBIT	-16 -16	64% 64% -
Net Profit	-23 -23	37% 37% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Iterum Therapeutics Plc Stock News

Neutral

GlobeNewsWire

●

about 8 hours ago

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics 9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics

Neutral

GlobeNewsWire

●

14 days ago

Iterum Therapeutics Announces Partnership for Commercialization Services

U.S. Commercial Launch of ORLYNVAH TM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant path...

Neutral

GlobeNewsWire

●

about one month ago

Iterum Therapeutics Announces Extension of Term of Promissory Note

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. (“Pfizer”) has agreed to extend the term for payment of the regulatory...

More Iterum Therapeutics Plc News

Company Profile

Iterum Therapeutics Plc is a pharmaceutical company which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Head office	Ireland
CEO	Corey Fishman
Employees	14
Founded	2015
Website	www.iterumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now